MINNEAPOLIS, Sept. 29, 2016 /PRNewswire-iReach/ -- BRTI Life Sciences a Minnesota - based company, recently published a journal article entitled "3D Cell Culture in a Self Assembled Nanofiber Environment" by Chai et al. The article demonstrates how BRTI's Cell-Mate3D(TM) matrix technology can be used to create 3D cultures for tumor modeling by embedding cancer cells into the matrix. Cultures are analyzed using flow cytometry, immunostaining, histological staining, mechanical properties testing, and migration studies, which illustrates the utility of the matrix to biomedical researchers.
Photo - http://photos.prnewswire.com/prnh/20160928/413011
The artice also describes the properties of the matrix, and how the martix is formed through poly-electrolytic-complexing between two biopolymers, hyaluronic acid and chitosan. Please visit http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0162853 to view the article.
About PLOS ONE
The world's first multidisciplinary Open Access journal. PLOS ONE accepts scientifically rigorous research, regardless of novelty. PLOS ONE's broad scope provides a platform to publish primary research including interdisciplinary and replication studies as well as negative results. The journal's publication criteria are based on high ethical standards and rigor of the methodology and conclusions reported.
About BRTI Life Sciences
Bioactive Regenerative Therapeutics, Inc. (dba: BRTI Life Sciences) offers biomedical researchers chemically defined, tissue-like, and injectable 3D cell culture matrices. The BRTI biomimetic matrix technologies are translatable and create an ideal cell microenvironment for applications in regenerative medicine, disease modeling, and cancer research. Cell-Mate3D(TM) is commercially available in kit form. Information and pricing can be found at www.BRTILifeSciences.com or by contacting: Scott Brush, VP Sales and Marketing 1-855-849-2784.
Media Contact:Scott Brush, BRTI Life Sciences, 855-849-2784, sbrush@BRTILifeSciences.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE BRTI Life Sciences
